Evidence map›Paper›PMID 29143876›Full record

ArticleCurrent microbiology2018

Deregulation of Genes Associated with Alternate Drug Resistance Mechanisms in Mycobacterium tuberculosis.

Kalpana Sriraman, Kayzad Nilgiriwala, Dhananjaya Saranath, Anirvan Chatterjee, Nerges Mistry

Abstract read
PubMed Publisher
In one paragraph

Article in Current microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Rapid detection of rifampin resistance inMicrobiology spectrum · 2025
    Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Kalpana SriramanThe Foundation for Medical Research, 84-A, R.G. Thadani Marg, Worli, Mumbai, 400 018, India.
Kayzad NilgiriwalaThe Foundation for Medical Research, 84-A, R.G. Thadani Marg, Worli, Mumbai, 400 018, India.
Dhananjaya SaranathThe Foundation for Medical Research, 84-A, R.G. Thadani Marg, Worli, Mumbai, 400 018, India.
Anirvan ChatterjeeThe Foundation for Medical Research, 84-A, R.G. Thadani Marg, Worli, Mumbai, 400 018, India.
Nerges MistryThe Foundation for Medical Research, 84-A, R.G. Thadani Marg, Worli, Mumbai, 400 018, India. fmr@fmrindia.org.
Foundation for Medical Research · INIndian Institute of Technology Bombay · IN

Funding

Department of Science and Technology, Government of India SB/SO/HS-0065/2013
6 · The paper itself

Abstract

Alternate mechanisms of drug resistance involving intrinsic defense pathways play an important role in development of drug resistance. Deregulation of drug efflux, cellular metabolism, and DNA repair have been indicated to have effect on drug tolerance and persistence. Here we chose eight genes from these pathways to investigate their association with development of multidrug resistance (MDR). We generated mono drug resistant and MDR strains of rifampicin and isoniazid and examined the differential expression of genes belonging to efflux, DNA repair and cell wall lipid synthesis pathways. Rv1687c, recB, ppsD and embC genes showed significant (P <0.05) upregulation in mono-resistant (both rifampicin and isoniazid) as well as MDR strains. mmr showed significant upregulation with rifampicin resistance while Rv1457c showed significant upregulation only with mono-resistant strains. Highest expression change was observed with Rv1687c and ppsD. The study identified potential key genes that are significantly associated with development of drug resistance in vitro. These genes may help identify clinical strains predisposed to acquiring drug resistance in patients during the course of treatment or help in management of MDR forms of tuberculosis.

Indexed as

Drug Resistance, Multiple, BacterialAntitubercular AgentsBacterial ProteinsDown-RegulationGene Expression Regulation, BacterialHumansIsoniazidMicrobial Sensitivity TestsMycobacterium tuberculosisRifampinTuberculosisAntitubercular AgentsBacterial ProteinsIsoniazidRifampin

Identifiers

PMID29143876
OpenAlexW2768530704

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.